ArticleMedComm2026
Nicotinamide N-Methyltransferase Epigenetically Activates Fibronectin 1 Through H3K9me3 Remodeling in Clear Cell Renal Cell Carcinoma.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) is among the most prevalent malignancies of the urinary system. Patients with advanced ccRCC have poor clinical outcomes. This study aimed to investigate the role of nicotinamide N-methyltransferase (NNMT) in ccRCC. Multiomics analyses revealed aberrant expression of two enzymes in the nicotinamide metabolic pathway, both of which are associated with poor prognosis, with NNMT exhibiting the most pronounced alteration. NNMT modulation per se induces a malignant phenotype, irrespective of substrate or product supplementation. Mechanistically, using western blotting and chromatin immunoprecipitation assays, we demonstrated that NNMT decreases S-adenosylmethionine, thereby reducing histone H3 lysine 9 trimethylation (H3K9me3) at the fibronectin 1 (FN1) promoter and activating FN1 transcription. Exogenous FN1 rescued the migration and invasion in NNMT knockout cells. In clinical specimens, NNMT expression levels were markedly elevated in tumor tissues and correlated with tumor stage. NNMT inhibitor suppressed FN1 expression and tumor progression both in vitro and in vivo. Collectively, our findings establish NNMT as a pivotal epigenetic regulator that drives ccRCC progression through extracellular matrix remodeling, providing novel early-stage diagnostic and therapeutic strategies for ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.